ArticleOncoTargets and therapy2020

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer.

Liang Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.